Analyst Ratings

Upgrades, downgrades, and outlook changes from major analysts.

Coverage of analyst actions including upgrades, downgrades, initiations, and price-target changes. This category tracks how institutional research influences market perception, momentum shifts, and short-term price behavior.

Articles

1,435 total articles

Bernstein Maintains Outperform on Figure Technology, Sees $72 Target as Tokenization Momentum Builds

Bernstein Maintains Outperform on Figure Technology, Sees $72 Target as Tokenization Momentum Builds

Bernstein has reiterated its Outperform rating on Figure Technology (NASDAQ:FIGR) and set a $72.00 price target, implying roughly 15% upside from the current share price of $62.49. The firm named Figure its "top pick for 2026," citing the company’s focus as a "pure play tokenization platform for credit," and highlighted new product development and …

Truist Keeps Buy Rating on MannKind, Sees Upside to $9 as FDA Label Change Supports Afrezza Adoption

Truist Keeps Buy Rating on MannKind, Sees Upside to $9 as FDA Label Change Supports Afrezza Adoption

Truist Securities reaffirmed a Buy rating and $9 price target for MannKind (MNKD), highlighting an FDA-approved label update for Afrezza that clarifies starting mealtime dosing for patients switching from subcutaneous insulin. The firm models Afrezza peak sales of $171 million and calls the label revision an incremental positive for broader adoptio…

Truist Upholds Hold on VF Corp as Brand Results Show Mixed Momentum

Truist Upholds Hold on VF Corp as Brand Results Show Mixed Momentum

Truist Securities reaffirmed a Hold rating and an $18.00 price target on VF Corp, noting a recent modest shift in investor sentiment and mixed brand-level trends. The stock is trading above the target at $20.01 after a near 60% six-month rally, while valuation metrics remain elevated. Other brokerages have moved price targets in both directions, re…

Truist Lifts Gilead Sciences Price Target to $145, Cites Yeztugo Momentum and Pipeline Updates

Truist Lifts Gilead Sciences Price Target to $145, Cites Yeztugo Momentum and Pipeline Updates

Truist Securities raised its price target for Gilead Sciences to $145 from $140 while retaining a Buy rating, citing updated launch guidance and stronger prescription trends for the company’s HIV drug Yeztugo. The move follows Gilead’s fiscal 2025 pre-report and adjustments to near-term commercialization expectations across several products, and co…

Truist Lifts Nuvation Bio Target to $13, Cites Strong Ibtrozi Uptake

Truist Lifts Nuvation Bio Target to $13, Cites Strong Ibtrozi Uptake

Truist Securities increased its price target on Nuvation Bio Inc to $13.00 from $11.00 and kept a Buy rating following the company’s fourth-quarter 2025 pre-report and a one-on-one meeting with management. The firm highlighted stronger-than-expected early uptake of Ibtrozi and the drug’s positioning in the ROS1 treatment landscape, while noting pot…